Skip to main content
Premium Trial:

Request an Annual Quote

LGC Clinical Diagnostics Seraseq Inherited Cancer DNA Mix v2

LGC Clinical Diagnostics has launched the Seraseq Inherited Cancer DNA Mix v2, a comprehensive reference material designed to support the validation and daily quality control of cancer predisposition assays. The product is designed to address the most challenging-to-detect mutations, ensuring that labs can confidently provide accurate, actionable insights for patients at risk of hereditary cancer syndromes. According to LGC, the new reference material includes 61 clinically relevant variants across 56 cancer-associated genes, about 2.5 times more targets than the previous version. These include rare and complex mutations such as the MSH2 Boland inversion and PMS2 pseudogene homologous variants.